Cargando…

Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication

BACKGROUND: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial supply of energy to support neuronal activity. METHOD: We pursued one te...

Descripción completa

Detalles Bibliográficos
Autores principales: Oades, Robert D, Dauvermann, Maria R, Schimmelmann, Benno G, Schwarz, Markus J, Myint, Aye-Mu
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889842/
https://www.ncbi.nlm.nih.gov/pubmed/20509936
http://dx.doi.org/10.1186/1744-9081-6-29
_version_ 1782182722081390592
author Oades, Robert D
Dauvermann, Maria R
Schimmelmann, Benno G
Schwarz, Markus J
Myint, Aye-Mu
author_facet Oades, Robert D
Dauvermann, Maria R
Schimmelmann, Benno G
Schwarz, Markus J
Myint, Aye-Mu
author_sort Oades, Robert D
collection PubMed
description BACKGROUND: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial supply of energy to support neuronal activity. METHOD: We pursued one test of the idea with measures of a neurotrophin reflecting glial integrity (S100B) and the influences of 8 cytokines on the metabolism of amino-acids, and of tryptophan/kynurenine to neuroprotective or potentially toxic products that could modulate glial function. Serum samples from 21 medication-naïve children with ADHD, 21 typically-developing controls, 14 medicated children with ADHD and 7 healthy siblings were analysed in this preliminary exploration of group differences and associations. RESULTS: There were no marked group differences in levels of S100B, no major imbalance in the ratios of pro- to anti-inflammatory interleukins nor in the metabolism of kynurenine to toxic metabolites in ADHD. However, four trends are described that may be worthy of closer examination in a more extensive study. First, S100B levels tended to be lower in ADHD children that did not show oppositional/conduct problems. Second, in medicated children raised interleukin levels showed a trend to normalisation. Third, while across all children the sensitivity to allergy reflected increased levels of IL-16 and IL-10, the latter showed a significant inverse relationship to measures of S100B in the ADHD group. Fourthly, against expectations healthy controls tended to show higher levels of toxic 3-hydroxykynurenine (3 HK) than those with ADHD. CONCLUSIONS: Thus, there were no clear signs (S100B) that the glial functions were compromised in ADHD. However, other markers of glial function require examination. Nonetheless there is preliminary evidence that a minor imbalance of the immunological system was improved on medication. Finally, if lower levels of the potentially toxic 3 HK in ADHD children were confirmed this could reflect a reduction of normal pruning processes in the brain that would be consistent with delayed maturation (supported here by associations with amino-acid metabolism) and a reduced metabolic source of energy.
format Text
id pubmed-2889842
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28898422010-06-23 Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication Oades, Robert D Dauvermann, Maria R Schimmelmann, Benno G Schwarz, Markus J Myint, Aye-Mu Behav Brain Funct Research BACKGROUND: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial supply of energy to support neuronal activity. METHOD: We pursued one test of the idea with measures of a neurotrophin reflecting glial integrity (S100B) and the influences of 8 cytokines on the metabolism of amino-acids, and of tryptophan/kynurenine to neuroprotective or potentially toxic products that could modulate glial function. Serum samples from 21 medication-naïve children with ADHD, 21 typically-developing controls, 14 medicated children with ADHD and 7 healthy siblings were analysed in this preliminary exploration of group differences and associations. RESULTS: There were no marked group differences in levels of S100B, no major imbalance in the ratios of pro- to anti-inflammatory interleukins nor in the metabolism of kynurenine to toxic metabolites in ADHD. However, four trends are described that may be worthy of closer examination in a more extensive study. First, S100B levels tended to be lower in ADHD children that did not show oppositional/conduct problems. Second, in medicated children raised interleukin levels showed a trend to normalisation. Third, while across all children the sensitivity to allergy reflected increased levels of IL-16 and IL-10, the latter showed a significant inverse relationship to measures of S100B in the ADHD group. Fourthly, against expectations healthy controls tended to show higher levels of toxic 3-hydroxykynurenine (3 HK) than those with ADHD. CONCLUSIONS: Thus, there were no clear signs (S100B) that the glial functions were compromised in ADHD. However, other markers of glial function require examination. Nonetheless there is preliminary evidence that a minor imbalance of the immunological system was improved on medication. Finally, if lower levels of the potentially toxic 3 HK in ADHD children were confirmed this could reflect a reduction of normal pruning processes in the brain that would be consistent with delayed maturation (supported here by associations with amino-acid metabolism) and a reduced metabolic source of energy. BioMed Central 2010-05-28 /pmc/articles/PMC2889842/ /pubmed/20509936 http://dx.doi.org/10.1186/1744-9081-6-29 Text en Copyright ©2010 Oades et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Oades, Robert D
Dauvermann, Maria R
Schimmelmann, Benno G
Schwarz, Markus J
Myint, Aye-Mu
Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
title Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
title_full Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
title_fullStr Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
title_full_unstemmed Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
title_short Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
title_sort attention-deficit hyperactivity disorder (adhd) and glial integrity: s100b, cytokines and kynurenine metabolism - effects of medication
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889842/
https://www.ncbi.nlm.nih.gov/pubmed/20509936
http://dx.doi.org/10.1186/1744-9081-6-29
work_keys_str_mv AT oadesrobertd attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication
AT dauvermannmariar attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication
AT schimmelmannbennog attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication
AT schwarzmarkusj attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication
AT myintayemu attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication